Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119767) titled 'Study on the Efficacy and Safety of Vericiguat in Patients with Acute Myocardial Infarction Combined with Mildly Reduced Ejection Fraction (LVEF: 45-50%)' on March 3.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The First Hospital of Jilin University
Condition:
Heart failure
Intervention:
Group A (Experimental Group):On the basis of guideline-directed standard treatment (ACEI/ARB/ARNI, ß-blockers, diuretics, SGLT2i, etc.), oral vericiguat 5 mg is administered once daily. Treatment should start after the diagnosis of acute myocardial infarction, once the patient is stable a...